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nificance but was positive (r 5 0.34, P 5 0.09). After CTRParathyroid function as a determinant of the response to
treatment, serum calcium increased in both groups, and despitecalcitriol treatment in the hemodialysis patient.
marked differences in basal PTH (Rs, 197 6 25 vs. NRs, 969 6Background. Bolus calcitriol (CTR) is used for the treat-
85 pg/ml), an inverse correlation between ionized calcium andment of secondary hyperparathyroidism in dialysis patients.
basal/maximal PTH was present in both groups (Rs, r 5 20.61,Although CTR treatment reduces parathyroid hormone (PTH)
levels in many dialysis patients, a significant number fail to P 5 0.001, and NRs, r 5 20.60, P 5 0.001).
respond. Conclusions. (a) Dynamic testing of parathyroid function
Methods. To learn whether or not an analysis of parathyroid provided insights into the pathophysiology of PTH secretion
function could further illuminate the response to CTR, a PTH- in hemodialysis patients. (b) The magnitude of hyperparathy-
calcium curve was performed before and after at least two roidism was the most important predictor of the response to
months of CTR treatment in 50 hemodialysis patients with a CTR. (c) Before CTR treatment, PTH was sensitive to calcium
predialysis intact PTH of greater than 300 pg/ml. in Rs, and serum calcium was PTH driven in NRs, and (d)
Results. For the entire group (N 5 50), CTR treatment re- after the CTR-induced increase in serum calcium, calcium sup-
sulted in a 24% reduction in predialysis (basal) PTH from pressed basal PTH relative to maximal PTH in both groups.
773 6 54 to 583 6 71 pg/ml (P , 0.001), whereas ionized
calcium increased from 1.10 6 0.02 to 1.22 6 0.02 mm (P ,
0.001); however, maximal and minimal PTH did not change
Since 1984, when bolus intravenous calcitriol (CTR)from pre-CTR values. Based on whether or not the basal PTH
decreased by 40% or more during CTR treatment, patients was first introduced as a treatment for renal hyperpara-
were divided into responders (Rs, N 5 25) and nonresponders thyroidism [1], several studies have shown that bolus oral
(NRs, N 5 25). Before CTR, the NR group was characterized
and intravenous CTR have similar efficacy in decreasingby a greater basal (959 6 80 vs. 586 6 51 pg/ml, P , 0.001)
parathyroid hormone (PTH) levels in dialysis patientsand maximal (1899 6 170 vs. 1172 6 108 pg/ml, P , 0.001)
PTH and serum phosphorus (6.14 6 0.25 vs. 5.14 6 0.34 mg/ [2, 3]. However, even though treatment with CTR re-
dl, P , 0.01). Logistical regression analysis showed that the duces PTH levels in many dialysis patients, a significant
pre-CTR basal PTH was the most important predictor of the number of patients fail to respond to CTR treatmentpost-CTR basal PTH, and a pre-CTR basal PTH of 750 pg/
[2, 4, 5]. These failures have been ascribed to intrinsicml represented a 50% probability of a response. Basal PTH
correlated with the ionized calcium in the NR group (r 5 0.59, factors associated with large, hyperplastic parathyroid
P 5 0.002) but not in the R group (r 5 0.06, P 5 NS). In the glands such as nodular hyperplasia [6–8] and a decrease
R group, an inverse correlation was present between ionized in vitamin D receptor density [8, 9], and extrinsic factorscalcium and the basal/maximal PTH ratio, an indicator of
such as the failure to control the serum phosphoruswhether calcium is suppressing basal PTH secretion relative
[2, 10, 11].to the maximal secretory capacity (maximal PTH) r 5 20.55,
P 5 0.004; in the NR group, this correlation approached sig- The PTH-calcium curve has been used to evaluate the
effectiveness of CTR treatment in several studies [2, 10,
12–15]. Dynamic testing of parathyroid function providesKey words: calcium, hyperparathyroidism, parathyroid hormone, dial-
ysis. information on the maximal PTH response to hypocal-
cemia and maximal PTH suppression during hypercalce-
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mia, and these should be less affected by changes inand in revised form January 15, 1999
Accepted for publication March 1, 1999 serum calcium than the predialysis PTH. Thus, an analy-
sis of these two parameters should provide a greater 1999 by the International Society of Nephrology
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understanding of the PTH response to CTR than only (Lleida). All patients were treated with CTR for at least
2 months, and the mean duration was 3.07 months.the predialysis PTH level. In addition, other parameters
obtained during dynamic testing of parathyroid function Among the four hemodialysis units, the magnitude of
hyperparathyroidism and the serum calcium values weresuch as the set point of calcium and the ratio of basal
to maximal PTH, the latter reflecting the effect of serum similar in the Badajoz, Tenerife, and Cordoba hemodial-
ysis units. When these groups were combined and com-calcium on basal PTH secretion relative to maximal
PTH, may help in understanding the pathophysiology of pared with the Lleida patients, the basal PTH (705 6
53 vs. 1078 6 143 pg/ml, P , 0.01) and the maximalPTH secretion in the hemodialysis patient.
This study was performed in 50 hemodialysis patients PTH (1414 6 105 vs. 2088 6 362 pg/ml, P 5 0.02), as
well as the serum calcium concentration (1.08 6 0.02 vs.in whom the PTH-calcium curve was obtained before
and after treatment with bolus CTR. The goals of this 1.21 6 0.04 mm, P 5 0.001), were greater in the Lleida
patients.study in hemodialysis patients with secondary hyper-
parathyroidism were to determine whether or not (a) an During CTR treatment, the dialysate calcium concen-
tration was maintained at 2.5 mEq/liter. All patients wereanalysis of parathyroid function would aid in understand
the response to CTR treatment and whether (b) the dialyzed for 12 to 14 hours per week and had Kt/V values
greater than 1.2. In the four hemodialysis units, the dialy-predialysis serum calcium level affected PTH secretion
differently in responders (Rs) and nonresponders (NRs) sate bicarbonate concentration was 35 or 36 mEq/liter,
and the dialysate magnesium concentration ranged fromboth before and after CTR treatment.
1 to 1.5 mEq/liter. The serum aluminum concentration
was monitored during the study and was less than 35 mg/
METHODS
liter in all patients.
Fifty hemodialysis patients from four hemodialysis As has been described previously [10, 17, 18], to deter-
units in Spain were studied before and after treatment mine maximal PTH secretion and suppression, low (1
with CTR. These hemodialysis units were in Badajoz mEq/liter) and high (4 mEq/liter) calcium hemodialyzes
(N 5 19), Tenerife (N 5 9), Lleida (N 5 9), and Cordoba were performed on separate days within one week. These
(N 5 13), and the study was approved by the Human studies were performed immediately before and after
Studies Committee at the four hospitals. Although some CTR treatment. Before CTR treatment, three patients
patients were included in previous reports [16, 17], this did not have high calcium studies, and two of these same
study differs because the detailed analysis of parathyroid patients did not have high calcium studies after CTR
function provides information on the pathophysiology treatment. From the data obtained during dialysis-
of the PTH response to CTR treatment. The mean age induced hypocalcemia and hypercalcemia, the following
of the patients was 53 6 2 years, and the female/male criteria were applied: (a) Basal PTH was the predialysis
distribution was 32 and 18, respectively. The duration of PTH level. (b) Maximal PTH was the highest PTH level
hemodialysis at entry was 83 6 8 months and was not observed in response to hypocalcemia and which an addi-
different among the four hemodialysis units. The primary tional reduction of the serum calcium did not further
phosphate binder was calcium carbonate; in seven pa- increase PTH; the maximal PTH level was achieved in
tients, aluminum hydroxide was added when serum phos- all patients. (c) Minimal PTH was the lowest PTH level
phorus was not adequately controlled with calcium car- during suppression by hypercalcemia and which a further
bonate. Patients had never received CTR or had not increase in the serum calcium did not result in any addi-
received CTR for at least three months before study tional decrease in PTH; the minimal PTH level was
entry. achieved in all patients. (d) The basal serum calcium was
The criteria for receiving CTR were a basal (predial- the serum ionized calcium concentration at the basal
ysis) PTH level of more than 300 pg/ml. In two hemodial- PTH. (e) The ratio of basal to maximal PTH was the
ysis units (Badajoz and Tenerife), patients were ran- basal PTH divided by the maximal PTH; this fraction
domly assigned to receive either twice or three times was multiplied by 100, and in normal volunteers, it is 20
weekly bolus oral or intravenous CTR. In the other two to 25% [19]. By correcting the actual PTH for the overall
hemodialysis units, the patients entering the study re- capacity to produce PTH (maximal PTH), a measure of
ceived twice or three times weekly bolus intravenous the relative degree of PTH stimulation is obtained. When
CTR. Of the 50 patients enrolled in the study, 38 patients the basal calcium is low, the basal to maximal PTH ratio
received intravenous CTR, and 12 patients received oral should be high, indicating that the parathyroid gland is
CTR. PTH values were similar in patients who received using more of its overall capacity to correct the low
oral and intravenous CTR (775 6 115 vs. 772 6 63 pg/ calcium. Conversely, a high basal calcium should be ac-
ml, respectively). The mean weekly CTR dose was 4.03 6 companied by a decrease in the basal to maximal PTH
0.14 mg, and the respective weekly CTR doses were 3.13 ratio. For an inverse correlation to be present between
calcium and the basal/maximal PTH, an increasing cal-mg (Badajoz), 4 mg (Tenerife and Cordoba), and 6 mg
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Table 1. Parameters of the parathyroid hormone (PTH)-calciumcium must decrease basal PTH relative to maximal PTH.
curve and serum phosphorus pre- and post-calcitriol treatment
However, for an inverse correlation to be present, it is in all patients and in responders and non-responders to
calcitriol treatmentnot necessary for basal PTH to decrease because maxi-
mal PTH could be increasing as basal PTH remains rela- All patients Responder Non-responder
(N 5 50) (N 5 25) (N 5 25)tively constant. (e) The set point of calcium was defined
Ionized calcium mmas we have done previously [10, 13, 18] as the serum
Pre 1.1060.02 1.1060.02 1.10 60.02calcium concentration at which maximal PTH secretion
Post 1.2260.22b 1.2760.03c 1.1760.02c,e
was reduced by 50%. The set point of calcium was also Phosphorus mg/dl
Pre 5.6460.22 5.1460.34 6.14 60.25bdefined by the method of Brown in which the set point
Post 6.5560.25b 5.8460.33d 7.2660.45c,eis the midrange of the PTH-calcium curve [20]. Basal PTH pg/ml
Pre 773654 586651 959 680aThe patients were divided into Rs and NRs based on
Post 583671b 197626a 969685awhether the predialysis (basal) PTH value decreased by
Maximal PTH pg/ml
40% or more in response to CTR treatment. This value Pre 15356112 11726108 1899 6170e
Post 13006187 599670c 20016312ewas selected because it represented the median for the
Minimal PTH pg/mltotal group of 50 patients and also was the mean CTR- Pre 261630 206632 314 650
Post 238633 127619c 344654einduced decrease in PTH observed in a recent prospec-
Basal/maximal PTH %tive study [2]. Because bolus oral and intravenous CTR
Pre 5262 5263 52 62
have been reported to induce a similar reduction in PTH Post 4463c 3363c 5463e
Set point (50%) mm[2, 3] and, more importantly, because the results of a
Pre 1.1060.01 1.1060.01 1.11 60.03
chi-square analysis in this study showed that the response Post 1.1760.01b 1.1760.02c 1.1860.02c
Set point (mid-range) mmto CTR was not different between patients receiving
Pre 1.0860.01 1.0860.02 1.08 60.03bolus oral and intravenous CTR, the 50 patients were Post 1.1360.01b 1.1360.02c 1.1360.02c
analyzed as a single group.
Data are mean 6 se.
Intact PTH was measured with an IRMA assay (Al- a Basal PTH post-calcitriol different by definition
b P , 0.001, c P , 0.01, d P , 0.05 pre- vs. post-calcitriollegro; Nichols Institute, San Juan Capistrano, CA, USA); e P , 0.01, f P , 0.05, responder vs. non-responder
normal values are 10 to 65 pg/ml. During the low- and
high-calcium studies, serum-ionized calcium was mea-
sured with a selective electrode in freshly obtained sam-
RESULTSples. At all other times, serum calcium as well as serum
phosphorus was measured with standard laboratory tech- As shown in Table 1, CTR treatment resulted in in-
creases in the serum calcium and phosphorus and theniques.
set point. CTR treatment also resulted in decreases in
Statistics the basal PTH and the basal/maximal PTH ratio. Maxi-
mal and minimal PTH did not change during CTR treat-For comparisons between two groups before and after
ment.CTR treatment, the unpaired or paired Student’s t-test
The patients were divided into R and NR groups basedwas used. The association between two variables was
on whether or not basal PTH decreased by 40% or moreassessed by Pearson’s linear correlation. One-way analy-
during CTR treatment. The respective changes in basalsis of variance was used for the comparison of three or
PTH with CTR treatment were 2389 6 35 (R) versus
more groups, and the Duncan test was the post hoc test
10 6 54 (NR) pg/ml; these were different by definition
used for intergroup comparison when the analysis of of the two groups. For the R (N 5 25) and NR (N 5
variance (ANOVA) was significant. Chi-square analysis 25) groups, the mean age, duration of dialysis, and sex
was performed to determine whether the response to distribution were not different (56 6 3 vs. 49 6 3 years,
CTR was different in patients receiving bolus oral or 70 6 12 vs. 96 6 11 months, and 7 male/18 female vs.
intravenous CTR. Stepwise multiple regression analysis 11 male/14 female patients, respectively). Furthermore,
was performed to determine which parameters best pre- the mean weekly CTR dose was not different between
dicted the basal PTH before and after CTR treatment. the R and NR groups (4.21 6 0.17 vs. 3.85 6 0.23 mg).
Similarly, stepwise logistic regression analysis was per- As shown in Table 1, the pre-CTR values for the serum
formed to predict which pre-CTR parameter best pre- calcium, basal/maximal PTH ratio, and set point were
dicted a response to CTR defined as a treatment-induced not different for the R and NR groups. However, serum
40 or 20% decrease in basal PTH. Results are shown as phosphorus, basal PTH, and maximal PTH were greater,
the mean 6 se, and a P value of less than 0.05 was and minimal PTH tended to be greater (P 5 0.07) in
the NR group.considered significant.
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The maximal PTH correlated with the serum calcium in
both the R (P 5 0.02) and NR (P 5 0.05) groups. The
basal/maximal PTH ratio was inversely correlated with
the serum calcium in the R group (P 5 0.004); conversely,
in the NR group, the correlation was positive and tended
to approach significance (P 5 0.09). Finally, the minimal
PTH correlated with the serum calcium in both the R
(P , 0.001) and NR (P 5 0.02) groups.
The post-CTR treatment values for the R and NR
groups are shown in Table 1. In addition to the defined
difference for basal PTH, both maximal PTH and mini-
mal PTH were less (P , 0.001) after CTR treatment in
Fig. 1. Logistic regression model to predict response to calcitriol treat- the R group. In the same group, serum phosphorus was
ment. Stepwise logistic regression analysis showed that the precalcitriol
less (P , 0.01), and serum calcium was greater (P ,basal parathyroid hormone (PTH) level was the most important pre-
dictor of the probability of a 40% reduction in basal PTH during 0.01). Associated with the greater serum calcium was a
calcitriol treatment. Using the previously mentioned model, a 50% lower basal/maximal PTH ratio (P , 0.001). It should
probability of a response (40% reduction in basal PTH) was observed
also be noted that in the R group, the decrease in basalat a precalcitriol basal PTH value of 750 pg/ml. At a basal PTH of 1200
pg/ml, the probability of a response to calcitriol was less than 20%, and PTH was greater (P , 0.01) than that for maximal PTH
at a basal PTH of 400 pg/ml, the probability of a response approached and minimal PTH; moreover, the decrease in maximal
80%.
PTH was greater (P , 0.05) than minimal PTH. Respec-
tive values for basal, maximal, and minimal PTH with
the post-CTR value as a percentage of the pre-CTR
value were 32 6 3, 51 6 3, and 64 6 6%, respectively.Stepwise logistic regression was performed to deter-
mine which parameters available before CTR treatment The change in the basal/maximal PTH ratio and in
basal, maximal, and minimal PTH values and thebest predicted a response to CTR. Pre-CTR calcium,
phosphorus, and PTH values (independent variables) rightward shift of the PTH-calcium curve produced by
CTR treatment are shown in Figure 3. The basal/maxi-were used in the logistic matrix to predict a 40 or 20%
post-CTR decrease in basal PTH (dependent variable). mal PTH ratio that reflects the relative degree of para-
thyroid gland sensitivity to the serum calcium decreasedFor a 40% decrease in basal PTH, the only significant
predictor was the pre-CTR basal PTH (P 5 0.013, odds in the R group from 52 6 3 to 33 6 3% (P , 0.001)
after CTR treatment as the serum calcium concentrationratio 0.9965 for each 1 pg/ml decrease in basal PTH,
95% CI, 0.994 to 0.9986). The use of pre-CTR minimal increased (Fig. 3A). Conversely, in the NR group, the
basal/maximal PTH ratio did not change despite the in-or maximal PTH values instead of basal PTH did not
improve the predictive power. The probability of a re- crease in serum calcium and a similar shift to the right
of the PTH-calcium curve (Fig. 3B). The magnitude ofsponse to CTR based on pre-CTR basal PTH values is
shown for the model in Figure 1. A 50% probability of the absolute reduction in PTH in the R group (Fig. 3C)
and the lack of a change in the NR group (Fig. 3D) cana response (40% reduction in basal PTH) was observed
at a pre-CTR basal PTH value of 750 pg/ml. At a basal be appreciated in the PTH-calcium curves shown in these
figures.PTH of 1200 pg/ml, the probability of a response to CTR
was less than 20%, and at a basal PTH of 400 pg/ml, the The post-CTR correlations between serum calcium
and the PTH parameters are shown for the R and NRprobability of a response approached 80%. For a 20%
decrease in basal PTH, the only significant predictor groups in Figure 4. For the R group in which significant
reductions in basal, maximal, and minimal PTH werewas the pre-CTR basal PTH level (P 5 0.02, odds ratio
0.9982). observed as a result of CTR treatment, the previously
significant pre-CTR correlations between calcium andBefore the CTR treatment, the predialysis serum cal-
cium concentration was highly correlated with the set maximal and minimal PTH were no longer present. The
correlation between serum calcium and basal PTH waspoint (50% and mid range) in the Rs [r 5 0.76, P ,
0.001 (50%) and r 5 0.70, P , 0.001 (mid range)] and essentially flat, as it was before CTR treatment. An in-
verse correlation was again present between serum cal-NRs [r 5 0.88, P , 0.001 (50%) and r 5 0.86, P , 0.001
(mid range)] groups. By contrast, as shown in Figure 2, cium and basal/maximal PTH (r 5 20.61, P 5 0.001).
Moreover, even though a marked post-CTR reductionseveral differences were observed between the R and
NR groups for the correlations between serum calcium in basal and maximal PTH was observed in the R group,
the combining of the pre- and post-CTR groups showedand the different PTH parameters. A significant correla-
tion was present between serum calcium and basal PTH that the inverse correlation between serum calcium and
basal/maximal PTH ratio represented a continuum within the NR group (P 5 0.002) but not in the R group.
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Fig. 2. Parathyroid function before calcitriol treatment in responders and nonresponders. The original group of 50 patients was divided into
responders and nonresponders based on whether a 40% reduction in the basal PTH was observed with calcitriol treatment. Shown in the left
panel are the correlations before calcitriol treatment in the responders (N 5 25) between serum calcium and basal PTH, maximal PTH, the basal/
maximal PTH ratio, and minimal PTH. Shown in the right panel are the correlations before calcitriol treatment in the nonresponders (N 5 25)
between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH.
Rodriguez et al: Parathyroid function and calcitriol 311
Fig. 3. Patterns of PTH secretion in respond-
ers and nonresponders. The mean basal/maxi-
mal PTH ratio (3100) is shown before (j)
and after (s) calcitriol treatment in (A and B)
and the absolute changes in basal and maximal
PTH are shown in (C and D). Symbols in C
and D are: (solid line) pre-CTR; (dashed line)
post-CTR; (n) PTHmax; (s) basal PTH; (h)
PTHmin. Before calcitriol treatment, the mean
basal/maximal PTH ratio was similar in the
responders (A; P , 0.001 pre- vs. post-CTR)
and nonresponders (B). In both groups, a simi-
lar shift to the right of the PTH-calcium curve
shifted was observed during calcitriol treat-
ment with sustained increases in the serum
calcium concentration. However, in only the
responders was the rightward shift in the PTH-
calcium curve associated with a decrease in
the mean basal/maximal PTH ratio. In (C and
D), the absolute values for basal, maximal,
and minimal PTH are shown. Before calcitriol
treatment, the basal and maximal PTH levels
were less in the responders (C) than the nonre-
sponders (D), and minimal PTH was not dif-
ferent. With calcitriol treatment, basal, maxi-
mal, and minimal PTH values decreased in
the responders (C), but were essentially un-
changed in the nonresponders (D).
progressive suppression of basal/maximal PTH as the between serum calcium and the basal/maximal PTH (r 5
20.60, P 5 0.001). This inverse correlation resulted be-serum calcium increased from pre- to post-CTR values
(r 5 20.69, P , 0.001). For the NR group in which basal, cause the slope of the correlation between serum calcium
and maximal PTH had increased from before CTR treat-maximal, and minimal PTH values had not changed from
pre-CTR values, the correlations between serum calcium ment (2755x to 5041x), and the slope for the correlation
between serum calcium and basal PTH had decreasedand the minimal and maximal PTH remained significant
and had even increased for maximal PTH. The correla- from before CTR treatment (1932x to 1311x).
The effect that the serum calcium, serum phosphorus,tion between serum calcium and basal PTH was positive
(r 5 0.34) and approached significance (P 5 0.09). Even and maximal PTH had on basal PTH before and after
CTR treatment was evaluated by stepwise multiple re-though basal and maximal PTH levels had not changed
after CTR treatment, an inverse correlation was present gression analysis in the R and NR groups (Table 2).
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Fig. 4. Parathyroid function after calcitriol treatment in responders and nonresponders. The original group of 50 patients was divided into
responders and nonresponders based on whether a 40% reduction in the basal PTH was observed with calcitriol treatment. Shown in the left
panel are the correlations after calcitriol treatment in the responders (N 5 25) between serum calcium and basal PTH, maximal PTH, the basal/
maximal PTH ratio, and minimal PTH. Shown in the right panel are the correlations after calcitriol treatment in the nonresponders (N 5 25)
between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH. Symbols are: (solid line) pre-CTR; (dashed
line) post-CTR; (dotted line in A) basal PTH; (dotted line in B) basal/maximum PTH.
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Table 2. Stepwise multiple regression analysis before and after sult in any differences in ionized calcium, basal/maximal
calcitriol (CTR) treatment with basal parathyroid hormone (PTH)
PTH, basal PTH, and maximal PTH values. Thus, atas the dependent variable and serum calcium and maximal PTH
as the independent variables least based on absolute post-CTR values, differences in
serum phosphorus did not seem to be responsible forS-Estb R2 addc t value P value
differences between the R and NR groups. However, as
Responder group, pre-CTRa
shown in Table 3, when the effect of serum phosphorusYes Pre-CTR basal calcium 20.38 0.113 22.9 50.007
Yes Pre-CTR maximal PTH 0.95 0.707 7.3 ,0.001 on the CTR-induced decrease in basal and maximal PTH
No Pre-CTR phosphorus 0.002 0.3 50.73 was evaluated, phosphorus appeared to have an effect.
R2 5 0.71
Although the delta ionized calcium was greater in theNon-responder group, pre-CTR
Yes Pre-CTR basal calcium 0.31 0.08 2.8 50.01 R than the NR group, intragroup differences in serum
Yes Pre-CTR maximal PTH 0.71 0.432 6.5 ,0.001 phosphorus did not result in differences in calcium. As
No Pre-CTR phosphorus 0.001 0.3 50.80
expected, the decrease in basal and maximal PTH wasR2 5 0.78
Responder group, post-CTR greater in the R group. However, the results also suggest
Yes Post-CTR basal calcium 20.33 0.095 22.8 50.01 that in each group, phosphorus appeared to have an
Yes Post-CTR maximal PTH 0.86 0.698 7.5 ,0.001
independent effect. In the NR group, despite no differ-Yes Post-CTR phosphorus 0.14 0.018 1.2 50.24
R2 5 0.73 ence in ionized calcium and delta ionized calcium, the
Non-responder group, post-CTR decrease in basal PTH was greater when the phosphorus
No Post-CTR basal calcium 0.011 0.8 50.44
was less than 6 mg/dl. The decrease in maximal PTHYes Post-CTR maximal PTH 0.77 0.587 5.7 ,0.001
No Post-CTR phosphorus 0.009 0.7 50.49 also tended to be greater for the absolute (P 5 0.06)
R2 5 0.59 and percentage (P 5 0.07) decrease in maximal PTH.
a Indicates that the variable is in the equation In the R group, the subgroup with the lower phosphorus
b The standardized regression coefficient
also seemed to have a better response. The percentagec The amount that would be added to or removed from R2 if this variable were
included in or removed from the model decrease in basal and maximal PTH was greater when
serum phosphorus was less than 6 mg/dl.
DISCUSSIONBefore CTR treatment in the R group, with basal PTH
In this study, PTH-calcium curves were performedas the dependent variable and basal calcium, phospho-
before and after CTR treatment in 50 hemodialysis pa-rus, and maximal PTH as independent variables, the
tients. We evaluated whether information obtained fromserum calcium had a strong negative effect (P , 0.01),
the PTH-calcium curve helped to understand the patho-and the maximal PTH had a strong positive effect (P ,
physiology of PTH secretion in renal hyperparathyroid-0.001) on the basal PTH. The remarkable finding in the
ism and in the response to CTR treatment. The separa-NR group was that the effect of serum calcium was not
tion of patients into R and NR groups resulted in distinctnegative but positive (P 5 0.01). The maximal PTH had
differences between the two groups that were recogniz-a strong positive effect (P , 0.001) on the basal PTH.
able before CTR treatment. Although an acute changeAfter CTR treatment in the R group, even with the
in serum calcium produced reciprocal changes in PTHincrease in serum calcium and the reduction in all PTH
secretion during dynamic testing in both the R and NRparameters, the effect of serum calcium remained nega-
groups, there was a remarkable difference in control oftive (P 5 0.01) and that of maximal PTH remained
PTH secretion between the R and NR groups duringstrongly positive (P , 0.001). After CTR treatment in
sustained changes in the predialysis serum calcium. Inthe NR group during which the serum calcium had in-
the R group, a higher serum calcium resulted in a lowercreased but maximal PTH did not decrease, the effect
basal PTH relative to the maximal secretory capacityof serum calcium was no longer positive, and the effect
(maximal PTH). Conversely, in the NR group, as theof maximal PTH remained strongly positive (P , 0.001).
serum calcium increased, basal PTH increased evenBecause serum phosphorus was greater in the NR than
more than maximal PTH, suggesting that basal PTHthe R group, it could have contributed to the failure to
secretion was poorly controlled by the prevailing serumrespond to CTR either by a direct effect on PTH secre-
calcium concentration. Finally, as was shown in previoustion or by acting to minimize the increase in serum cal-
studies [17, 18, 21, 22], CTR treatment in both the Rcium. To determine the effect of phosphorus, the R and
and NR groups induced a sustained increase in serumNR groups were subdivided based on a post-CTR serum
calcium with a rightward shift of the PTH-calcium curve.phosphorus of 6 mg/dl (Table 3). Although basal PTH
Besides differences in the magnitude of hyperparathy-was different by definition, other differences were pres-
roidism, the two groups were also characterized by differ-ent. Ionized calcium was greater, and the basal/maximal
ences in the PTH response to sustained changes in serumPTH ratio and maximal PTH were less in the R group.
Intragroup separation by serum phosphorus did not re- calcium. In the R group, the inverse correlation between
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Table 3. Effect of serum phosphorus on the response to calcitriol treatment in responder and non-responder groups
Responder Non-responder
Phosphorus Phosphorus Phosphorus Phosphorus
,6 mg/dl .6 mg/dl ,6 mg/dl .6 mg/dl
(N 5 15) (N 5 10) (N 5 6) (N 5 19)
Post-CTR
Ionized calcium mm 1.2960.05 1.24 60.03 1.1560.04a 1.1760.03
Phosphoruse mg/dl 4.6860.16 7.57 60.32 5.6260.16a 7.7860.37
Basal/maximal PTH % 3163 37 64 4965a 5765b
Basal PTHf pg/ml 167625 241 654 8546138 10056103
Maximal PTH pg/ml 577686 632 6122 17406241a 20846405b
Minimal PTH pg/ml 122619 125 642 4186113a 319662b
Difference between pre- and post-CTR
D Ionized calcium mm 0.1560.04 0.17 60.04 0.0360.03a 0.0860.02b
D Phosphorus mg/dl 0.4160.35 1.12 60.44 0.0860.48 1.45 60.28c
D Basal PTHf pg/ml 2418644 2347657 22526104 92651bc
D Basal PTHf % 27263 26165c 22266a 1065bc
D Maximal PTH pg/ml 2658661 24446106 23826150a 2556298bd
D Maximal PTH % 25564 24165c 21865a 8613bd
Data are mean 6 sd.
a P , 0.05 vs. Responder (Phosphorus , 6 mg/dl)
b P , 0.05 vs. Responder (Phosphorus . 6 mg/dl)
c P # 0.05 vs. Phosphorus , 6 mg/dl – same group
d P 5 0.06 or 0.07 vs. Phosphorus , 6 mg/dl – same group
e Phosphorus different between the two subgroups of Responders and Non-responders based on the definition of the subgroups
f Basal PTH different between the Responders and Non-responders based on the definition of the groups
basal/maximal PTH and serum calcium suggested that decreased more than the maximal secretory capacity
(maximal PTH).sustained increases in serum calcium inhibited basal PTH
secretion relative to the maximal secretory capacity As schematically drawn for the R group in Figure 5,
we suggest that changes in serum calcium can move the(maximal PTH). The result of the stepwise multiple re-
gression also supported this interpretation. Conversely, PTH-calcium curve in two directions, either primarily
vertically or horizontally. Acute changes in serum cal-in the NR group, a direct correlation was present be-
tween basal PTH and the serum calcium. Moreover, as cium produced rapid responses in PTH secretion in ac-
cordance with the traditional concepts of the primarilythe serum calcium increased, basal PTH secretion tended
to increase even more than the maximal secretory capac- vertically oriented sigmoidal PTH-calcium relationship.
However, as shown in Figure 3 and in previous studiesity (maximal PTH). Finally, stepwise multiple regression
also showed that the effect of calcium was positive. Thus, [17, 18, 21, 22], sustained changes in serum calcium shift
the PTH-calcium curve horizontally in the direction ofbefore CTR treatment, a sustained increase in the serum
calcium seemed to inhibit basal PTH secretion in the R the change in serum calcium. In such shifts of the PTH-
calcium curve in which new steady-state conditions pre-but not in the NR group. Furthermore, in the NR group,
the situation may be analogous to primary hyperparathy- vail, a leftward shift increases and a rightward shift de-
creases the basal/maximal PTH ratio. This shift of theroidism in which it is considered that PTH is driving the
serum calcium, even though an acute calcium infusion serum calcium to a new steady state results in calcium
having an effect on basal PTH secretion, but to a consid-rapidly decreases PTH secretion [23–27].
Calcitriol treatment together with the increases in se- erably lesser extent than that produced by acute changes
in serum calcium.rum calcium markedly reduced basal, maximal, and mini-
mal PTH values in the R group. The inverse relationship As has been shown in previous in vitro [28–30] and in
vivo [31] studies, an elevated phosphorus could directlybetween basal/maximal PTH and the serum calcium was
maintained post-CTR treatment and suggests that in the affect PTH secretion. After CTR treatment in both the R
and NR groups, basal PTH values were only marginallyR group, calcium continued to inhibit basal PTH secre-
tion. The results of the stepwise multiple regression also lower in patients with serum phosphorus values of less
than 6 mg/dl. However, when factored for serum phos-serve to support this conclusion. In the NR group, CTR
treatment did not change the basal, maximal, and mini- phorus and shown as the decrease from pre-CTR values,
the decrease in basal PTH was greater in both the Rmal PTH. Nonetheless, an inverse correlation, which was
not present before CTR treatment, was observed be- and NR groups in the patients with the lower serum
phosphorus. This effect of phosphorus was observedtween the basal/maximal PTH and serum calcium. Thus,
as the serum calcium increased, basal PTH secretion even though the absolute and delta serum calcium values
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only one factor of which the most important seems to
be the magnitude of hyperparathyroidism.
Although our study was solely a clinical study, the
distinct differences in parathyroid function and the re-
sponse to CTR between the R and NR groups suggest
the likelihood of differences in parathyroid gland size
[32] and pathology between the two groups. It is known
that the most severe hyperparathyroidism in dialysis pa-
tients is associated with nodular hyperplasia of the para-
thyroid gland [6, 7, 33–35]. As compared with diffuse
hyperplasia, nodular hyperplasia is characterized by a
greater parathyroid gland mass [7, 33–35], a more
marked decrease in vitamin D receptor density [8], a
greater parathyroid cell proliferative capacity [36], the
development of recurrent hyperparathyroidism after
parathyroidectomy [7, 36–39], an abnormal release of
PTH [40, 41], and the suggestion that parathyroid cells
from areas of nodular hyperplasia may be monoclonal
in origin [42, 43]. In this study, it would be expected
that in the NR group, especially in those patients with
hypercalcemia and marked elevations in basal and maxi-
mal PTH levels before CTR treatment, nodular hyper-
plasia would be the predominant pathologic lesion.
In conclusion, this study shows that (a) even before
CTR treatment, distinct differences in parathyroid func-
tion were present between the eventual Rs and NRs.
(b) Dynamic testing of parathyroid function provided a
physiologic framework that helped to understand the
response of hemodialysis patients to CTR treatment. (c)Fig. 5. Schematic representation of changes in parathyroid function
before and after calcitriol treatment in responders. A schematic repre- The magnitude of hyperparathyroidism was the most
sentation of the changes in the PTH-calcium curve is shown before
important predictor of the response to CTR. (d) In NRs(solid line) and after (dashed line) calcitriol treatment in the responder
group with PTH in (A) in absolute values and (B) as a percentage of to CTR, serum calcium was PTH driven. (e) In Rs to
maximal PTH. The figure is drawn to show that in both (A and B), the CTR, basal PTH secretion was sensitive to serum cal-
PTH-calcium curve moves both vertically at various serum calcium
cium. (f ) The basal/maximal PTH ratio functioned as anconcentrations in the classic sigmoidal PTH in response to acute changes
in serum calcium and horizontally in the direction of sustained changes indicator of parathyroid gland responsiveness to calcium,
in the serum calcium. As shown in (A), as the serum calcium increased and (g) an elevated serum phosphorus had an adverse
before calcitriol treatment, basal PTH remained constant even though
effect on the response to CTR.maximal PTH increased, and as a result, (B) the basal/maximal PTH
ratio decreased as the serum calcium increased. After calcitriol treat-
ment (A), both basal and maximal PTH markedly decreased markedly
in absolute values, and serum calcium increased from precalcitriol levels.
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